These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28587626)

  • 1. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
    Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
    Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
    Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
    J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
    Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
    Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
    Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
    Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
    Gianno F; Antonelli M; Di Dio T; Minasi S; Donofrio V; Buccoliero AM; Gardiman MP; Pollo B; Diomedi Camassei F; Rossi S; Novello M; Giangaspero F; Arcella A; Gessi M; Buttarelli FR
    Am J Surg Pathol; 2021 Feb; 45(2):200-204. PubMed ID: 33428336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
    Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
    Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
    Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
    Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
    Kasper LH; Baker SJ
    Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.
    Oliveira VF; De Sousa GR; Dos Santos AC; Saggioro FP; Machado HR; de Oliveira RS; Tone LG; Valera ET
    Childs Nerv Syst; 2021 Feb; 37(2):375-382. PubMed ID: 32766947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling.
    Chen KY; Bush K; Klein RH; Cervantes V; Lewis N; Naqvi A; Carcaboso AM; Lechpammer M; Knoepfler PS
    Commun Biol; 2020 Jul; 3(1):363. PubMed ID: 32647372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
    Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
    Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
    Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
    Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
    Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
    Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
    Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants.
    Bressan RB; Southgate B; Ferguson KM; Blin C; Grant V; Alfazema N; Wills JC; Marques-Torrejon MA; Morrison GM; Ashmore J; Robertson F; Williams CAC; Bradley L; von Kriegsheim A; Anderson RA; Tomlinson SR; Pollard SM
    Cell Stem Cell; 2021 May; 28(5):877-893.e9. PubMed ID: 33631116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.